Alexander Levitzki
Overview
Explore the profile of Alexander Levitzki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1605
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levitzki A, Klein S
Proc Natl Acad Sci U S A
. 2019 May;
116(24):11579-11586.
PMID: 31076554
Since the 1980s there has been a drive toward personalized targeted therapy for cancer. "Targeted cancer therapy" originally focused on inhibiting essential tumor survival factors, primarily protein tyrosine kinases. The...
2.
Su S, Flashner-Abramson E, Klein S, Gal M, Lee R, Wu J, et al.
Mol Cancer Ther
. 2018 Feb;
17(5):931-942.
PMID: 29440449
The small-molecule drug NT157 has demonstrated promising efficacy in preclinical models of a number of different cancer types, reflecting activity against both cancer cells and the tumor microenvironment. Two known...
3.
Langut Y, Talhami A, Mamidi S, Shir A, Zigler M, Joubran S, et al.
Proc Natl Acad Sci U S A
. 2017 Dec;
114(52):13655-13660.
PMID: 29229829
There is an urgent need for an effective treatment for metastatic prostate cancer (PC). Prostate tumors invariably overexpress prostate surface membrane antigen (PSMA). We designed a nonviral vector, PEI-PEG-DUPA (PPD),...
4.
Shir A, Klein S, Sagiv-Barfi I, Geiger T, Zigler M, Langut Y, et al.
J Infect Dis
. 2017 Nov;
217(2):288-297.
PMID: 29149330
Superantigens (SAgs) are extremely potent bacterial toxins, which evoke a virulent immune response, inducing nonspecific T-cell proliferation, rapid cytokine release, and lethal toxic shock, for which there is no effective...
5.
Langut Y, Edinger N, Flashner-Abramson E, Melamed-Book N, Lebendiker M, Levi-Kalisman Y, et al.
Oncotarget
. 2017 Apr;
8(15):24046-24062.
PMID: 28445962
The treatment of metastatic androgen-resistant prostate cancer remains a challenge. We describe a protein vector that selectively delivers synthetic dsRNA, polyinosinic/polycytidylic acid (polyIC), to prostate tumors by targeting prostate specific...
6.
Edinger N, Lebendiker M, Klein S, Zigler M, Langut Y, Levitzki A
PLoS One
. 2016 Sep;
11(9):e0162321.
PMID: 27598772
Selective delivery of drugs to tumor cells can increase potency and reduce toxicity. In this study, we describe a novel recombinant chimeric protein, dsRBEC, which can bind polyIC and deliver...
7.
Zigler M, Shir A, Joubran S, Sagalov A, Klein S, Edinger N, et al.
Cancer Immunol Res
. 2016 Jun;
4(8):688-97.
PMID: 27241844
The development of targeted therapies that affect multiple signaling pathways and stimulate antitumor immunity is greatly needed. About 20% of patients with breast cancer overexpress HER2. Small molecules and antibodies...
8.
Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, et al.
Mol Cancer Ther
. 2014 Oct;
13(12):2827-39.
PMID: 25267499
Insulin-like growth factor (IGF) signaling is associated with castrate-resistant prostate cancer (CRPC) progression. Insulin receptor substrates 1 and 2 (IRS1/2) mediate mitogenic and antiapoptotic signaling from IGF1 receptor (IGF1R), insulin...
9.
Engelberg D, Perlman R, Levitzki A
Cell Signal
. 2014 Sep;
26(12):2865-78.
PMID: 25218923
In the very first article that appeared in Cellular Signalling, published in its inaugural issue in October 1989, we reviewed signal transduction pathways in Saccharomyces cerevisiae. Although this yeast was...
10.
Joubran S, Zigler M, Pessah N, Klein S, Shir A, Edinger N, et al.
Bioconjug Chem
. 2014 Aug;
25(9):1644-54.
PMID: 25121341
The delivery of nucleic acids into cells is an attractive approach for cancer therapy. Polyethylenimine (PEI) is among the most efficient nonviral carriers. Recent studies have demonstrated that PEI can...